Form 4: BDX Executive Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Becton Dickinson & Co. EVP Michael Feld sold 74 shares of common stock for $196.08 per share under a pre-arranged 10b5-1 plan.
Summary
- Michael Feld, Executive Vice President, Chief Research Officer, and President of Life Sciences at Becton Dickinson and Company (BDX), reported a transaction.
- The transaction involved the disposition of 74 shares of BDX Common Stock.
- The shares were sold at a price of $196.08 per share.
- The transaction date was December 26, 2025.
- Following this transaction, Michael Feld beneficially owns 16,506 shares of Common Stock.
- This sale was executed pursuant to a Rule 10b5-1 plan, which was adopted by Michael Feld on February 7, 2025.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is generally considered a neutral event with no immediate positive or negative implications for the company's fundamentals.
Future Outlook
The filing does not provide any forward-looking statements or guidance beyond the scheduled transaction date.
Industry Context
This filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: A routine, pre-scheduled insider sale of a small number of shares is unlikely to have a significant impact on shareholder sentiment or the company's stock price.
Key Dates
| Date | Description |
|---|---|
| February 7, 2025 | Date the Rule 10b5-1 plan was adopted by Michael Feld. |
| December 26, 2025 | Date of the reported transaction (sale of common stock). |
| December 29, 2025 | Date the Statement of Changes in Beneficial Ownership was signed by Donna Kalazdy, by power of attorney from Michael Feld. |
Recommendation
holdThe reported transaction is a pre-scheduled sale by an executive under a Rule 10b5-1 plan, which is a common practice for managing personal finances and diversifying holdings. It does not inherently signal a change in the company's fundamentals or future prospects, nor is the amount significant enough to suggest a shift in executive confidence. Therefore, a 'hold' recommendation is appropriate based solely on this filing, as it provides no new information to alter an existing investment thesis.
Keywords
Becton Dickinson, BDX, Michael Feld, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.